Epithelial immune regulation of inflammatory airway diseases: Chronic rhinosinusitis with nasal polyps (CRSwNP).

Allergologie Select Pub Date : 2022-04-29 eCollection Date: 2022-01-01 DOI:10.5414/ALX02296E
Ludger Klimek, Jan Hagemann, Hans-Jürgen Welkoborsky, Mandy Cuevas, Ingrid Casper, Ulrike Förster-Ruhrmann, Felix Klimek, Constantin A Hintschich, Tilman Huppertz, Christoph Bergmann, Peter-Valentin Tomazic, Sven Becker
{"title":"Epithelial immune regulation of inflammatory airway diseases: Chronic rhinosinusitis with nasal polyps (CRSwNP).","authors":"Ludger Klimek, Jan Hagemann, Hans-Jürgen Welkoborsky, Mandy Cuevas, Ingrid Casper, Ulrike Förster-Ruhrmann, Felix Klimek, Constantin A Hintschich, Tilman Huppertz, Christoph Bergmann, Peter-Valentin Tomazic, Sven Becker","doi":"10.5414/ALX02296E","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The epithelial immune regulation is an essential and protective feature of the barrier function of the mucous membranes of the airways. Damage to the epithelial barrier can result in chronic inflammatory diseases, such as chronic rhinosinusitis (CRS) or bronchial asthma. Thymic stromal lymphopoietin (TSLP) is a central regulator in the epithelial barrier function and is associated with type 2 (T2) and non-T2 inflammation.</p><p><strong>Materials and methods: </strong>The immunology of chronic rhinosinusitis with polyposis nasi (CRSwNP) was analyzed in a literature search, and the existing evidence was determined through searches in Medline, Pubmed as well as the national and international study and guideline registers and the Cochrane Library. Human studies or studies on human cells that were published between 2010 and 2020 and in which the immune mechanisms of TSLP in T2 and non-T2 inflammation were examined were considered.</p><p><strong>Results: </strong>TSLP is an epithelial cytokine (alarmin) and a central regulator of the immune reaction, especially in the case of chronic airway inflammation. Induction of TSLP is implicated in the pathogenesis of many diseases like CRS and triggers a cascade of subsequent inflammatory reactions.</p><p><strong>Conclusion: </strong>Treatment with TSLP-blocking monoclonal antibodies could therefore open up interesting therapeutic options. The long-term safety and effectiveness of TSLP blockade has yet to be investigated.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"6 ","pages":"148-166"},"PeriodicalIF":0.0000,"publicationDate":"2022-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9097524/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologie Select","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/ALX02296E","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The epithelial immune regulation is an essential and protective feature of the barrier function of the mucous membranes of the airways. Damage to the epithelial barrier can result in chronic inflammatory diseases, such as chronic rhinosinusitis (CRS) or bronchial asthma. Thymic stromal lymphopoietin (TSLP) is a central regulator in the epithelial barrier function and is associated with type 2 (T2) and non-T2 inflammation.

Materials and methods: The immunology of chronic rhinosinusitis with polyposis nasi (CRSwNP) was analyzed in a literature search, and the existing evidence was determined through searches in Medline, Pubmed as well as the national and international study and guideline registers and the Cochrane Library. Human studies or studies on human cells that were published between 2010 and 2020 and in which the immune mechanisms of TSLP in T2 and non-T2 inflammation were examined were considered.

Results: TSLP is an epithelial cytokine (alarmin) and a central regulator of the immune reaction, especially in the case of chronic airway inflammation. Induction of TSLP is implicated in the pathogenesis of many diseases like CRS and triggers a cascade of subsequent inflammatory reactions.

Conclusion: Treatment with TSLP-blocking monoclonal antibodies could therefore open up interesting therapeutic options. The long-term safety and effectiveness of TSLP blockade has yet to be investigated.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
炎症性气道疾病的上皮免疫调节:慢性鼻炎伴鼻息肉(CRSwNP)。
背景:上皮免疫调节是呼吸道粘膜屏障功能的基本保护功能。上皮屏障受损可导致慢性炎症性疾病,如慢性鼻炎(CRS)或支气管哮喘。胸腺基质淋巴细胞生成素(TSLP)是上皮屏障功能的核心调节因子,与2型(T2)和非T2型炎症有关:通过文献检索分析了慢性鼻窦炎伴鼻息肉病(CRSwNP)的免疫学,并通过在 Medline、Pubmed 以及国内和国际研究与指南登记册和 Cochrane 图书馆中的检索确定了现有证据。研究考虑了2010年至2020年间发表的人类研究或关于人类细胞的研究,这些研究考察了TSLP在T2和非T2炎症中的免疫机制:TSLP是一种上皮细胞因子(警报素),是免疫反应的核心调节因子,尤其是在慢性气道炎症的情况下。TSLP的诱导与许多疾病(如CRS)的发病机制有关,并引发一连串的后续炎症反应:因此,使用TSLP阻断单克隆抗体进行治疗可能会带来有趣的治疗选择。TSLP阻断疗法的长期安全性和有效性还有待研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Vegan diets from an allergy point of view - Position paper of the DGAKI working group on food allergy. Clinical endpoints in allergen immunotherapy: State of the art 2022. Allergic asthma: An indication for allergen immunotherapy. Allergen challenge tests in allergen immunotherapy: State of the art. Real-life evidence in allergen immunotherapy: Moving forward with mHealth apps.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1